Mycophenolate mofetil versus methotrexate for prevention of acute graft‐versus‐host disease in patients receiving allogeneic hematopoietic stem cell transplantation
Referencias
Additional references
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47(2‐3):85‐118. [PUBMED: 10878285]
Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines 3: rating the quality of evidence ‐ introduction. Journal of Clinical Epidemiology 2011;64(4):401‐6. [PUBMED: 21208779]
Bensinger W. Individual patient data meta‐analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplantation 2006;38(8):539‐46. [PUBMED: 16953207]
Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation 2004;34(7):621‐5. [PUBMED: 15300236]
Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate‐ and non‐methotrexate‐containing graft‐versus‐host disease prophylaxis regimens. Biology of Blood and Marrow Transplantation 2005;11(5):383‐8. [PUBMED: 15846292]
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88.
Egger M, Smith DG, Schnider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34.
Ferrara JL, Levine JE, Reddy P, Holler E. Graft‐versus‐host disease. Lancet 2009;373(9674):1550‐61. [PUBMED: 19282026]
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation 2005;11(12):945‐56. [PUBMED: 16338616]
Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft‐versus‐host disease and for chronic graft‐versus‐host disease according to National Institutes of Health consensus criteria. Blood 2011;117(11):3214‐9. [PUBMED: 21263156]
Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [PUBMED: 21195583]
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso‐Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence ‐ risk of bias. Journal of Clinical Epidemiology 2011;64(4):407‐15. [PUBMED: 21247734]
Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence ‐ publication bias. Journal of Clinical Epidemiology 2011;64(12):1277‐82. [PUBMED: 21802904]
Guyatt G, Oxman AD, Kunz R, Brozek J, Alonso‐Coello P, Rind D, et al. GRADE guidelines: 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology 2011;64(12):1283‐93. [PUBMED: 21839614]
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294‐302. [PUBMED: 21803546]
Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence ‐ indirectness. Journal of Clinical Epidemiology 2011;64(12):1303‐10. [PUBMED: 21802903]
Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 2005;5:13. [PUBMED: 15840177]
Kharfan‐Dabaja MA, Pidala J, Kumar A, Terasawa T, Djulbegovic B. Comparing efficacy of reduced‐toxicity allogeneic hematopoietic cell transplantation with conventional chemo‐(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplantation 2012;47(9):1164‐70. [PUBMED: 22562081]
Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic stem cell transplantation. Blood 2012;120(8):1545‐51. [PUBMED: 22700725]
Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009;87(6):785‐94. [PUBMED: 19300178]
Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001;98(7):2043‐51. [PUBMED: 11567988]
Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta‐analysis of prospective clinical trials. JAMA 2009;301(22):2349‐61. [PUBMED: 19509382]
McSweeney P, Abhyankar S, Petersen F. Tacrolimus and mycophenolate mofetil for GVHD prevention after unrelated donor transplants. Blood 2003;102:2654a.
Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft‐versus‐host disease prophylaxis after stem cell transplantation from HLA‐identical siblings. Bone Marrow Transplantation 2005;35(11):1089‐93. [PUBMED: 15821769]
Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched‐sibling donor allogeneic stem‐cell transplantations conditioned with fludarabine and low‐dose total body irradiation. Biology of Blood and Marrow Transplantation 2006;12(2):217‐25. [PUBMED: 16443519]
Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, et al. A pilot study of tacrolimus and mycophenolate mofetil graft‐versus‐host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biology of Blood and Marrow Transplantation 2004;10(4):246‐58. [PUBMED: 15077223]
Perkins J, Field T, Kim J, Kharfan‐Dabaja MA, Fernandez H, Ayala E, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft‐versus‐host disease prophylaxis. Biology of Blood and Marrow Transplantation 2010;16(7):937‐47. [PUBMED: 20102746]
Pidala J, Anasetti C. Glucocorticoid‐refractory acute graft‐versus‐host disease. Biology of Blood and Marrow Transplantation 2010;16(11):1504‐18. [PUBMED: 20096359]
Pinana JL, Valcarcel D, Fernandez‐Aviles F, Martino R, Rovira M, Barba P, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced‐intensity conditioning PBSCT from HLA‐identical siblings. Bone Marrow Transplantation 2010;45(9):1449‐56. [PUBMED: 20140024]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1.6. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Schmeding M, Kiessling A, Neuhaus R, Heidenhain C, Bahra M, Neuhaus P, et al. Mycophenolate mofetil monotherapy in liver transplantation: 5‐year follow‐up of a prospective randomized trial. Transplantation 2011;92(8):923‐9. [PUBMED: 21832958]
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft‐versus‐host syndrome in man. A long‐term clinicopathologic study of 20 Seattle patients. American Journal of Medicine 1980;69(2):204‐17. [PUBMED: 6996481]
Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, et al. Stable mixed hematopoietic chimerism in DLA‐identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89(8):3048‐54. [PUBMED: 9108426]
Svahn BM, Ringden O, Remberger M. Treatment costs and survival in patients with grades III‐IV acute graft‐versus‐host disease after allogenic hematopoietic stem cell transplantation during three decades. Transplantation 2006;81(11):1600‐3. [PUBMED: 16770251]
Svahn BM, Remberger M, Alvin O, Karlsson H, Ringden O. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re‐transplantation. Bone Marrow Transplantation 2012;47(5):706‐15. [PUBMED: 21874063]
Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8(1):1‐16.
Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft‐versus‐host disease among lethally irradiated dogs given DLA‐nonidentical unrelated marrow grafts. Blood 1998;91(7):2581‐7. [PUBMED: 9516160]
Zuk DM, Pearson GJ. Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients‐‐a systematic review. Transplantation Reviews 2009;23(3):171‐7. [PUBMED: 19345081]
